

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Wands *et al.*

SERIAL NUMBER: To Be Assigned

EXAMINER: Not Yet Assigned

FILING DATE: July 11, 2001

ART UNIT: To Be Assigned

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

July 11, 2001  
Boston, Massachusetts

Assistant Commissioner for Patents  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

Prior to examination, please amend the application as follows.

**In the specification:**

On page 1, line 2, after the title, insert:

APPLICANTS: Wands et al.

FILED: Herewith

This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.

APPLICANTS: Wands et al.

FILED: Herewith

In the claims:

Cancel claims 1-15, 23-36 and 38.

Add new claims 39-56.

APPLICANTS: Wands et al.

FILED: Herewith

39. The method of claim 16, wherein said compound is an antibody or fragment thereof which binds to HAAH.
40. The method of claim 39, wherein said antibody or fragment thereof binds to an epitope in the catalytic domain of HAAH.
41. The method of claim 16, wherein said compound is a single chain Fv molecule.
42. The method of claim 16, wherein said compound is a FB50 antibody.
43. The method of claim 16, wherein said compound is a FB50 single chain Fv molecule.
44. The method of claim 19, wherein said mutation comprises a substitution or deletion of a histidine residue in said catalytic domain of HAAH.
45. The method of claim 19, wherein said mutation is located between residues 650-700 of SEQ ID NO:2.
46. The method of claim 19, wherein said mutation is a substitution or deletion at residue 675 of SEQ ID NO:2.
47. The method of claim 19, wherein said mutation is a substitution or deletion at residue 679 of SEQ ID NO:2.
48. The method of claim 19, wherein said mutation is a substitution or deletion at residue 690 of SEQ ID NO:2.
49. The method of claim 19, wherein said compound is administered directly into a tumor site.
50. The method of claim 19, wherein said compound is administered systemically.
51. The method of claim 16, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.
52. The method of claim 16, wherein said tumor is a cancer of the central nervous system.
53. The method of claim 16, wherein said tumor is a hepatocellular carcinoma.
54. The method of claim 16, wherein said tumor is a cholangiocarcinoma.
55. The method of claim 16, wherein said tumor is a glioblastoma.
56. The method of claim 16, wherein said tumor is a neuroblastoma.

APPLICANTS: Wands et al.

FILED: Herewith

## REMARKS

Claims 16-22, 37, and 39-56 are pending, claims 1-15, 23-36 and 38 having been canceled as being drawn to a non-elected invention. New claims 39-56 have been added; these claims are supported by disclosure on page 5, lines 1-25, of the specification. New claims 51-52 are supported by disclosure on page 1, lines 25-31, and new claims 53-54 are supported by disclosure on page 22, lines 5-6, of the specification. New claims 55 and 56 are supported by disclosure on page 17, line 29, and on page 42, lines 30-33, of the specification.

No new matter has been added by this amendment.

## CONCLUSION

Applicants believe that the claims are in condition for allowance. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21486-032.

Respectfully submitted,

  
Ingrid A. Beattie, Reg. No. 42,306  
Attorney for Applicants  
c/o MINTZ LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel.: (617) 542 6000  
Fax: (617) 542-2241

1540146)

APPLICANTS: Wands et al.

FILED: Herewith

--45. The method of claim 19, wherein said mutation is located between residues 650-700 of SEQ ID NO:2. --

--46. The method of claim 19, wherein said mutation is a substitution or deletion at residue 675 of SEQ ID NO:2. --

--47. The method of claim 19, wherein said mutation is a substitution or deletion at residue 679 of SEQ ID NO:2.--

--48. The method of claim 19, wherein said mutation is a substitution or deletion at residue 690 of SEQ ID NO:2.--

--49. The method of claim 19, wherein said compound is administered directly into a tumor site.--

--50. The method of claim 19, wherein said compound is administered systemically.--

--51. The method of claim 16, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.--

--52. The method of claim 16, wherein said tumor is a cancer of the central nervous system--.

--53. The method of claim 16, wherein said tumor is a hepatocellular carcinoma.--

--54. The method of claim 16, wherein said tumor is a cholangiocarcinoma.--

--55. The method of claim 16, wherein said neoplasm is a glioblastoma--

--56. The method of claim 16, wherein said neoplasm is a neuroblastoma--

APPLICANTS: Wands et al.

FILED: Herewith

Appendix

In the specification:

On page 1, line 2, after the title, insert:

--This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.--

In the claims:

Cancel claims 1-15, 23-36 and 38.

Add new claims 39-56.

--39. The method of claim 16, wherein said compound is an antibody or fragment thereof which binds to HAAH.--

--40. The method of claim 39, wherein said antibody or fragment thereof binds to an epitope in the catalytic domain of HAAH.--

--41. The method of claim 16, wherein said compound is a single chain Fv molecule.--

--42. The method of claim 16, wherein said compound is a FB50 antibody.--

--43. The method of claim 16, wherein said compound is a FB50 single chain Fv molecule.--

--44. The method of claim 19, wherein said mutation comprises a substitution or deletion of a histidine residue in said catalytic domain of HAAH.--